Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Haemonetics Corp (HAE)

Haemonetics Corp (HAE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,834,208
  • Shares Outstanding, K 46,810
  • Annual Sales, $ 1,361 M
  • Annual Income, $ 167,680 K
  • EBIT $ 277 M
  • EBITDA $ 407 M
  • 60-Month Beta 0.30
  • Price/Sales 2.78
  • Price/Cash Flow 11.21
  • Price/Book 4.58

Options Overview Details

View History
  • Implied Volatility 30.32% (-2.21%)
  • Historical Volatility 80.08%
  • IV Percentile 2%
  • IV Rank 2.75%
  • IV High 72.27% on 10/21/25
  • IV Low 29.13% on 06/13/25
  • Expected Move (DTE 14) 3.23 (3.85%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 48
  • Volume Avg (30-Day) 470
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 6,857
  • Open Int (30-Day) 7,562
  • Expected Range 80.58 to 87.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.27
  • Number of Estimates 5
  • High Estimate 1.28
  • Low Estimate 1.26
  • Prior Year 1.19
  • Growth Rate Est. (year over year) +6.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.96 +67.75%
on 11/05/25
84.19 -0.45%
on 12/04/25
+33.43 (+66.36%)
since 11/04/25
3-Month
47.31 +77.13%
on 09/26/25
84.19 -0.45%
on 12/04/25
+29.73 (+54.97%)
since 09/04/25
52-Week
47.31 +77.13%
on 09/26/25
85.00 -1.40%
on 12/10/24
+0.30 (+0.36%)
since 12/04/24

Most Recent Stories

More News
Teleflex, Solventum, Haemonetics, Centene, and Molina Healthcare Shares Skyrocket, What You Need To Know

Teleflex, Solventum, Haemonetics, Centene, and Molina Healthcare Shares Skyrocket, What You Need To Know

SOLV : 85.26 (+0.01%)
TFX : 118.86 (-0.22%)
MOH : 150.57 (+0.99%)
CNC : 38.85 (+0.10%)
HAE : 83.81 (+2.32%)
3 Reasons to Sell HAE and 1 Stock to Buy Instead

3 Reasons to Sell HAE and 1 Stock to Buy Instead

HAE : 83.81 (+2.32%)
1 Mooning Stock with Impressive Fundamentals and 2 We Ignore

1 Mooning Stock with Impressive Fundamentals and 2 We Ignore

TDC : 29.75 (-1.82%)
FROG : 62.12 (-0.74%)
HAE : 83.81 (+2.32%)
5 Insightful Analyst Questions From Haemonetics’s Q3 Earnings Call

5 Insightful Analyst Questions From Haemonetics’s Q3 Earnings Call

HAE : 83.81 (+2.32%)
HAE Q3 Deep Dive: Margin Expansion and Portfolio Rationalization Drive Outperformance

HAE Q3 Deep Dive: Margin Expansion and Portfolio Rationalization Drive Outperformance

HAE : 83.81 (+2.32%)
Why Are Haemonetics (HAE) Shares Soaring Today

Why Are Haemonetics (HAE) Shares Soaring Today

HAE : 83.81 (+2.32%)
Haemonetics (NYSE:HAE) Delivers Impressive Q3, Stock Jumps 12.8%

Haemonetics (NYSE:HAE) Delivers Impressive Q3, Stock Jumps 12.8%

HAE : 83.81 (+2.32%)
Haemonetics: Fiscal Q2 Earnings Snapshot

Haemonetics: Fiscal Q2 Earnings Snapshot

HAE : 83.81 (+2.32%)
Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Financial release and supplemental presentation accessible online

HAE : 83.81 (+2.32%)
What To Expect From Haemonetics’s (HAE) Q3 Earnings

What To Expect From Haemonetics’s (HAE) Q3 Earnings

HAE : 83.81 (+2.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Haemonetics Corp. provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood...

See More

Key Turning Points

3rd Resistance Point 87.52
2nd Resistance Point 85.86
1st Resistance Point 84.83
Last Price 83.81
1st Support Level 82.14
2nd Support Level 80.48
3rd Support Level 79.45

See More

52-Week High 85.00
Last Price 83.81
Fibonacci 61.8% 70.60
Fibonacci 50% 66.16
Fibonacci 38.2% 61.71
52-Week Low 47.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar